初始血小板与淋巴细胞比值作为局限期小细胞肺癌的预后因素。
Initial platelet-to-lymphocyte count as prognostic factor in limited-stage small cell lung cancer.
机构信息
Radiation Oncology Department of Thoracic Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Institute, Liaoning, Shenyang 110042, PR China.
出版信息
Biomark Med. 2019 Mar;13(4):249-258. doi: 10.2217/bmm-2018-0415. Epub 2019 Jan 9.
AIM
To assessed the prognostic significance of pretreatment platelet-to-lymphocyte ratio (PLR) in patients with limited-stage small cell lung cancer (LS-SCLC).
METHODS
We retrospectively analyzed 286 patients with LS-SCLC.
RESULTS
Sixty received chemotherapy alone, 158 sequential chemo- and radiotherapy, 38 concurrent chemo- and radiotherapy and 30 surgery combined with therapy. The cut-off value of pretreatment PLR was 152.1. The median progression free survival (PFS) and overall survival (OS) in the low and high PLR groups were 27.4 versus 19.5 (p = 0.002) and 14.9 versus 11.4 (p = 0.003) months. Multivariate analysis confirmed that PLR was an independent prognostic factor of OS (hazard ratio = 1.326; p = 0.040) and PFS (hazard ratio = 1.306; p = 0.044), respectively.
CONCLUSION
Pretreatment PLR is an independent prognostic factor of OS and PFS in patients with LS-SCLC.
目的
评估局限期小细胞肺癌（LS-SCLC）患者治疗前血小板与淋巴细胞比值（PLR）的预后意义。
方法
我们回顾性分析了 286 例 LS-SCLC 患者。
结果
60 例患者接受单纯化疗，158 例患者接受序贯化疗和放疗，38 例患者接受同步化疗和放疗，30 例患者接受手术联合治疗。治疗前 PLR 的截断值为 152.1。低 PLR 组和高 PLR 组的中位无进展生存期（PFS）和总生存期（OS）分别为 27.4 个月和 19.5 个月（p = 0.002），14.9 个月和 11.4 个月（p = 0.003）。多因素分析证实，PLR 是 OS（风险比 = 1.326；p = 0.040）和 PFS（风险比 = 1.306；p = 0.044）的独立预后因素。
结论
治疗前 PLR 是 LS-SCLC 患者 OS 和 PFS 的独立预后因素。
Zotero 插件